Recognized for Leadership Advancing Innovation in Oncology and Healthcare Technology
SAN DIEGO—January 23, 2026 — Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, today announced that its Chief Executive Officer, John Gu, has been selected as one of The Healthcare Technology Report’s Top CEOs of 2025.
The annual list recognizes healthcare technology leaders whose strategic vision and execution are driving progress across precision medicine, translational science, and advanced research platforms. Gu was selected for his leadership in advancing innovative preclinical and translational solutions that support more predictive oncology drug development.
Since becoming CEO, Gu has led Crown Bioscience through sustained global growth, expanding scientific capabilities and reinforcing the company’s position as a trusted partner to biopharmaceutical and biotechnology organizations worldwide. Under his leadership, the company has continued to invest in patient-derived models, translational platforms, and integrated research services designed to accelerate the development of new cancer therapies.
“Being named among The Healthcare Technology Report’s Top CEOs is a great honor,” said Gu. “This recognition reflects the dedication and expertise of the entire Crown Bioscience team, whose commitment to scientific rigor and innovation helps bring new therapies closer to patients.”
The Top CEOs of 2025 list highlights executives who successfully navigate complex scientific, technological, and regulatory environments while aligning innovation, operational excellence, and long-term strategy to advance healthcare. Gu was recognized for connecting cutting-edge science with scalable global operations in support of translational drug development.
Media Inquiries:
Crown Bioscience
Sarah Martin-Tyrrell
pr@crownbio.com